XII Congress Brazilian Society of Surgery Oncology

Breast carcinoma in situ

Dr Renato Cagnacci Neto - Camargo Cancer Center, Sao Paulo, Brazil

I’m going to present an article later at the best of SSO. It’s about breast carcinoma in situ, ductal carcinoma in situ, and the use of Oncotype for predicting local recurrence. It’s a new article, it was published this year, 2015, in the first semester and it’s very interesting research because it shows that we can use Oncotype, just like in the invasive cancers but also in in situ cancers in order to predict local recurrence and perhaps do less aggressive treatments when Oncotype says it’s a low risk situation. Usually for breast carcinoma in situ, even though it’s a simple disease, a very initial disease, we treat it as aggressively as invasive breast cancer with surgery and radiation. We’ve always tried to select patients to treat with surgery only and perhaps not using radiotherapy because it’s a costly treatment and not all countries have so easily radiation treatment. So we’ve always tried to select patients to treat with surgery only and perhaps Oncotype will give us, or at least it will help us, reaching that answer. Oncotype is a genetic signature, if the test says that the patient has a genetic signature of low risk, in that case local recurrence risk, we can select those patients not to undergo radiation therapy, just surgery.

How was your experience at this Latin American event?

I believe it’s a very important congress for Latin America because there aren’t many surgical oncology congresses in Latin America. Actually, I believe that’s the only one so it’s a very large congress with many international doctors and presenters from very good cancer centres. So I believe it’s a nice congress for all Latin America to attend.